Exoprobes is developing an innovative and unique platform for early diagnosis and monitoring of neurodegenerative diseases, by analyzing biomarkers in body fluids such as blood or saliva.

We improve the patient’s quality of life by allowing specific and timely treatment, saving time, money and lives.

Exoprobes is developing an innovative and unique platform for early diagnosis and monitoring of neurodegenerative diseases, by analyzing biomarkers in body fluids such as blood or saliva.

We improve the patient’s quality of life by allowing specific and timely treatment, saving time, money and lives.

Benefits

Early Diagnosis

 

Our technology can detect nanovesicles associated to the early onset of Neurodegenerative diseases

Reduced invasiveness

 

Blood or saliva sample
instead of cerebrospinal fluid
(CSF)

User friendly

 

Rapid test
with common
laboratory equipment

Our Technology

 

Innovative nanotechnological solutions for the analysis of predictive pathological biomarkers, contained in circulating extracellular vesicles.

We are developing the first nanobiotechnology liquid biopsy platform for the early diagnosis of neurodegenerative diseases. Exoprobes nanoprobes will be able to detect, isolate and quantify distinctive biomarkers carried by extracellular vesicles, circulating in liquid biological matrices which can be easily removed, such as blood or saliva samples. The studies will be carried out using various methodologies, including three-dimensional culture systems (Organoids, Organs-on-chip) capable of producing physiologically more accurate disease models than traditional two-dimensional (2D) cultures. Faithfully replicating the architecture and microenvironment in vivo would allow a better understanding of the complex molecular mechanisms, essential for the development of neurodegenerative diseases, in order to increase the chances of identifying potential specific biomarkers and therapeutic targets.

Our Technology

 

Innovative nanotechnological solutions for the analysis of predictive pathological biomarkers, contained in circulating extracellular vesicles.

We are developing the first nanobiotechnology liquid biopsy platform for the early diagnosis of neurodegenerative diseases. Exoprobes nanoprobes will be able to detect, isolate and quantify distinctive biomarkers carried by extracellular vesicles, circulating in liquid biological matrices which can be easily removed, such as blood or saliva samples. The studies will be carried out using various methodologies, including three-dimensional culture systems (Organoids, Organs-on-chip) capable of producing physiologically more accurate disease models than traditional two-dimensional (2D) cultures. Faithfully replicating the architecture and microenvironment in vivo would allow a better understanding of the complex molecular mechanisms, essential for the development of neurodegenerative diseases, in order to increase the chances of identifying potential specific biomarkers and therapeutic targets.

The team


The multidisciplinary Exoprobes team, made up of professionals with skills ranging from science to business, is the result of a path started in 2018. Our goal is focused on developing effective and innovative products, keeping the needs of patients and doctors at the center of the design and implementation process, thus improving the quality of life of patients suffering from these extremely disabling pathologies.

Oreste D'Ambrosio


Economist
Chief Financial Officer & co-Founder
 

Silvestro Turtoro


Pharmaceutical Biotechnologist
Chief Executive Officer & Founder

Alessandro Bortolani


Engineering
Industrial Management
Biz Developer & co-Founder

Guido Frigieri


Biotechnologist
COO & co-Founder
 

 

Awards

Get in touch

9 + 6 =